Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20240304061158N4
IRCT20240304061158N4
Recruiting
Phase 1

A Clinical trial to evaluate the safety and immunomodulatory efficacy of Byolic CC supplement compared to placebo in healthy adults

Behpad Teb Iranian0 sites90 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsImmunomodulatory effect on healthy volunteers.

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Immunomodulatory effect on healthy volunteers.
Sponsor
Behpad Teb Iranian
Enrollment
90
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Behpad Teb Iranian

Eligibility Criteria

Inclusion Criteria

  • •Health of volunteers

Exclusion Criteria

  • •usage of immunosuppressive drugs, including cytotoxic drugs and corticosteroids, or any other drug (within 4 weeks before the start of the study) that may interfere with the supplement used in this study (or other herbal products)
  • •drug and food allergies
  • •pregnancy and lactation
  • •cardiovascular, kidney, lung, liver, endocrine, hematological, neurological or psychiatric diseases, etc.)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
N/A
Phase I clinical trial to assess safety and immunogenicity of an MVA-based influenza H5 vaccine in healthy adultsfluInfluenza10047438
NL-OMON38408Erasmus MC, Universitair Medisch Centrum Rotterdam27
Recruiting
Phase 3
Clinical Trial of quadrivalent Papilloguard4 vaccine (Human Papillomavirus Types 6, 11, 16, 18) manufactured by Nivad Pharmed Salamat in comparison with GardasilGenital wart prevention.Anogenital (venereal) wartsA63.0
IRCT20240120060741N1ivad Pharmed Salamat670
Completed
Phase 1
A Phase I clinical trial to assess safety and immune response of Influenza vaccine of Serum Institute of India Limited in Adults.
CTRI/2011/09/002033Serum Institute of India Ltd Pune India40
Recruiting
Phase 3
A comparison of safety and immunogenicity between government of India approved Rabies pre exposure prophylaxis regimen and WHO Rabies pre exposure prophylaxis regime
CTRI/2023/09/057399Dr N R Ramesh Masthi
Active, Not Recruiting
Phase 1
Safety and immunogenicity of RNA-based vaccines against SARS-CoV-2 variants in healthy participantsProtection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2).MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.0Level: HLTClassification code 10084510Term: Coronavirus infectionsSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.1Level: LLTClassification code 10084529Term: 2019 novel coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2021-003458-22-DEBioNTech SE1,470